ZA200108173B - Use of pegylated interferon alpha in melanoma therapy. - Google Patents

Use of pegylated interferon alpha in melanoma therapy. Download PDF

Info

Publication number: ZA200108173B
Authority: ZA; South Africa
Prior art keywords: interferon alfa; patient; pegylated interferon; treatment; melanoma
Prior art date: 1999-04-08

Application number

ZA200108173A

Other languages

English (en)

Inventor

Mary Ellen Rybak

Esther Helen Rose

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-08

Filing date

2001-10-04

Publication date

2003-01-06

2001-10-04 Application filed by Schering Corp filed Critical Schering Corp

2003-01-06 Publication of ZA200108173B publication Critical patent/ZA200108173B/en

Links

201000001441 melanoma Diseases 0.000 title claims description 52
108010047761 Interferon-alpha Proteins 0.000 title claims description 36
102000006992 Interferon-alpha Human genes 0.000 title claims description 36
238000002560 therapeutic procedure Methods 0.000 title description 24
229950000038 interferon alfa Drugs 0.000 claims description 33
238000000034 method Methods 0.000 claims description 25
108010092851 peginterferon alfa-2b Proteins 0.000 claims description 20
230000004083 survival effect Effects 0.000 claims description 20
102000014150 Interferons Human genes 0.000 claims description 18
108010050904 Interferons Proteins 0.000 claims description 18
229940079322 interferon Drugs 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
208000030381 cutaneous melanoma Diseases 0.000 claims description 12
201000003708 skin melanoma Diseases 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 4
108010092853 peginterferon alfa-2a Proteins 0.000 claims description 4
239000000126 substance Substances 0.000 claims 10
229920001223 polyethylene glycol Polymers 0.000 description 15
108010078049 Interferon alpha-2 Proteins 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
230000003902 lesion Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 12
238000001356 surgical procedure Methods 0.000 description 12
229960003507 interferon alfa-2b Drugs 0.000 description 11
210000001165 lymph node Anatomy 0.000 description 9
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
230000003442 weekly effect Effects 0.000 description 8
230000000977 initiatory effect Effects 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
229940079593 drug Drugs 0.000 description 6
229960003521 interferon alfa-2a Drugs 0.000 description 6
238000012423 maintenance Methods 0.000 description 5
229940106366 pegintron Drugs 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
206010061819 Disease recurrence Diseases 0.000 description 4
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 4
102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
208000007433 Lymphatic Metastasis Diseases 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
238000013461 design Methods 0.000 description 4
238000009093 first-line therapy Methods 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229960005489 paracetamol Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 4
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
108010079944 Interferon-alpha2b Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
238000009098 adjuvant therapy Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
102100023915 Insulin Human genes 0.000 description 2
102100040018 Interferon alpha-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
206010027459 Metastases to lymph nodes Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000001099 axilla Anatomy 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
238000002224 dissection Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
210000004013 groin Anatomy 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000402 unacceptable toxicity Toxicity 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000014061 Extranodal Extension Diseases 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
208000035346 Margins of Excision Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000001934 delay Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
108010055511 interferon alfa-2c Proteins 0.000 description 1
108010006088 interferon alfa-n1 Proteins 0.000 description 1
229940109242 interferon alfa-n3 Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940065638 intron a Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000011270 sentinel node biopsy Methods 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
230000006016 thyroid dysfunction Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

ZA200108173A 1999-04-08 2001-10-04 Use of pegylated interferon alpha in melanoma therapy. ZA200108173B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28836699A	1999-04-08	1999-04-08

Publications (1)

Publication Number	Publication Date
ZA200108173B true ZA200108173B (en)	2003-01-06

Family

ID=23106795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200108173A ZA200108173B (en)	1999-04-08	2001-10-04	Use of pegylated interferon alpha in melanoma therapy.

Country Status (22)

Country	Link
EP (3)	EP1535622B1 (zh)
JP (1)	JP2000319195A (zh)
CN (1)	CN1390132A (zh)
AR (1)	AR023398A1 (zh)
AT (3)	ATE496631T1 (zh)
AU (1)	AU771569B2 (zh)
BR (1)	BR0009646A (zh)
CA (1)	CA2303992A1 (zh)
CO (1)	CO5170404A1 (zh)
CY (1)	CY1108922T1 (zh)
DE (3)	DE60020444T2 (zh)
DK (2)	DK1043026T3 (zh)
ES (2)	ES2319776T3 (zh)
HK (2)	HK1032349A1 (zh)
HU (1)	HU230057B1 (zh)
MY (1)	MY126763A (zh)
NO (1)	NO328111B1 (zh)
PE (1)	PE20010027A1 (zh)
PT (2)	PT1043026E (zh)
TW (1)	TWI292320B (zh)
WO (1)	WO2000061175A2 (zh)
ZA (1)	ZA200108173B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2828940C (en)	2011-03-10	2024-04-16	Provectus Pharmaceuticals, Inc.	Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4492537A (en)	1982-12-10	1985-01-08	Awerkamp John B	Fluid-operated oil or water well pump
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja)	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
PT730470E (pt)	1993-11-10	2002-08-30	Enzon Inc	Conjugados melhorados de interferao-polimero
US5766582A (en)	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
TW517067B (en)	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates

2000
- 2000-04-06 EP EP05002951A patent/EP1535622B1/en not_active Expired - Lifetime
- 2000-04-06 ES ES05002951T patent/ES2319776T3/es not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009129 patent/WO2000061175A2/en active Application Filing
- 2000-04-06 CA CA002303992A patent/CA2303992A1/en not_active Abandoned
- 2000-04-06 PT PT00107101T patent/PT1043026E/pt unknown
- 2000-04-06 DK DK00107101T patent/DK1043026T3/da active
- 2000-04-06 CN CN00808452A patent/CN1390132A/zh active Pending
- 2000-04-06 AT AT08020311T patent/ATE496631T1/de not_active IP Right Cessation
- 2000-04-06 AR ARP000101574A patent/AR023398A1/es unknown
- 2000-04-06 AU AU42046/00A patent/AU771569B2/en not_active Ceased
- 2000-04-06 CO CO00025236A patent/CO5170404A1/es not_active Application Discontinuation
- 2000-04-06 EP EP00107101A patent/EP1043026B1/en not_active Expired - Lifetime
- 2000-04-06 TW TW089106309A patent/TWI292320B/zh not_active IP Right Cessation
- 2000-04-06 PT PT05002951T patent/PT1535622E/pt unknown
- 2000-04-06 DE DE60020444T patent/DE60020444T2/de not_active Expired - Lifetime
- 2000-04-06 AT AT05002951T patent/ATE419001T1/de active
- 2000-04-06 AT AT00107101T patent/ATE296639T1/de active
- 2000-04-06 ES ES00107101T patent/ES2239954T3/es not_active Expired - Lifetime
- 2000-04-06 PE PE2000000310A patent/PE20010027A1/es not_active Application Discontinuation
- 2000-04-06 DE DE60041290T patent/DE60041290D1/de not_active Expired - Lifetime
- 2000-04-06 JP JP2000105524A patent/JP2000319195A/ja not_active Withdrawn
- 2000-04-06 DE DE60045591T patent/DE60045591D1/de not_active Expired - Lifetime
- 2000-04-06 DK DK05002951T patent/DK1535622T3/da active
- 2000-04-06 BR BR0009646-6A patent/BR0009646A/pt not_active Application Discontinuation
- 2000-04-06 HU HU0200775A patent/HU230057B1/hu not_active IP Right Cessation
- 2000-04-06 EP EP08020311A patent/EP2025344B1/en not_active Expired - Lifetime
- 2000-04-07 MY MYPI20001454A patent/MY126763A/en unknown
2001
- 2001-03-26 HK HK01102202A patent/HK1032349A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108173A patent/ZA200108173B/en unknown
- 2001-10-05 NO NO20014852A patent/NO328111B1/no not_active IP Right Cessation
2005
- 2005-11-02 HK HK05109748.1A patent/HK1075416A1/xx not_active IP Right Cessation
2009
- 2009-03-24 CY CY20091100351T patent/CY1108922T1/el unknown

Also Published As

Publication number	Publication date
DE60041290D1 (de)	2009-02-12
ATE419001T1 (de)	2009-01-15
HU230057B1 (hu)	2015-06-29
ES2319776T3 (es)	2009-05-12
EP1535622A1 (en)	2005-06-01
DE60020444D1 (de)	2005-07-07
ATE496631T1 (de)	2011-02-15
AU771569B2 (en)	2004-03-25
TWI292320B (en)	2008-01-11
WO2000061175A2 (en)	2000-10-19
CO5170404A1 (es)	2002-06-27
DK1043026T3 (da)	2005-07-04
EP2025344A1 (en)	2009-02-18
CN1390132A (zh)	2003-01-08
ATE296639T1 (de)	2005-06-15
AR023398A1 (es)	2002-09-04
EP2025344B1 (en)	2011-01-26
EP1043026A3 (en)	2000-12-20
ES2239954T3 (es)	2005-10-16
MY126763A (en)	2006-10-31
DK1535622T3 (da)	2009-04-20
DE60020444T2 (de)	2006-05-04
DE60045591D1 (de)	2011-03-10
WO2000061175A3 (en)	2001-02-01
EP1043026A2 (en)	2000-10-11
HK1075416A1 (en)	2005-12-16
NO20014852D0 (no)	2001-10-05
JP2000319195A (ja)	2000-11-21
NO20014852L (no)	2001-12-06
NO328111B1 (no)	2009-12-07
CA2303992A1 (en)	2000-10-08
HK1032349A1 (en)	2001-07-20
PT1043026E (pt)	2005-09-30
HUP0200775A3 (en)	2002-09-30
CY1108922T1 (el)	2014-07-02
PE20010027A1 (es)	2001-02-05
HUP0200775A2 (en)	2002-08-28
EP1043026B1 (en)	2005-06-01
EP1535622B1 (en)	2008-12-31
AU4204600A (en)	2000-11-14
PT1535622E (pt)	2009-03-19
BR0009646A (pt)	2002-02-05

Publication	Publication Date	Title
US7482014B2 (en)	2009-01-27	Melanoma therapy
US6362162B1 (en)	2002-03-26	CML Therapy
EP1043025B1 (en)	2005-06-01	Renal cell carcinoma treatment
US6605273B2 (en)	2003-08-12	Renal cell carcinoma treatment
JP2001288110A6 (ja)	2006-12-07	腎細胞ガン処置
EP2025344B1 (en)	2011-01-26	Melanoma Therapy
EP1043024B1 (en)	2005-06-08	Chronic myeloid leukemia (cml) therapy
MXPA00003345A (en)	2002-06-05	Melanoma therapy
JP2001288109A6 (ja)	2006-12-07	黒色腫治療
JP2001288109A (ja)	2001-10-16	黒色腫治療
MXPA00003346A (en)	2002-06-05	Chronic myeloid leukemia (cml) therapy